Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

HER2 Positivity in Breast Carcinoma: A Comparison of Chromogenic In Situ Hybridization With Fluorescence In Situ Hybridization in Tissue Microarrays, With Targeted Evaluation of Intratumoral Heterogeneity by In Situ Hybridization

HER2 Positivity in Breast Carcinoma: A Comparison of Chromogenic In Situ Hybridization With... TECHNICAL HER2 Positivity in Breast Carcinoma: A Comparison of Chromogenic In Situ Hybridization With Fluorescence In Situ Hybridization in Tissue Microarrays, With Targeted Evaluation of Intratumoral Heterogeneity by In Situ Hybridization Pequita Loring, BSc, Robert Cummins, BSc, Anthony O’Grady, MSc, and Elaine W. Kay, FRCPath a target-specific therapy that acts by inhibiting tyrosine kinase Abstract: An accurate and reproducible assay method for determin- 1,2 activity. Currently practiced laboratory methods for HER2 ing HER2 status is crucial, as a positive HER2 gene status is an eli- assessment include immunohistochemical (IHC) methods gibility requirement for Herceptin™ therapy. Although immunohis- (measuring increased protein expression) and fluorescence in tochemical (IHC) assessment is both practical and inexpensive, a Situ hybridization (FISH) and chromogenic in situ hybridiza- worrying trend of high false-positive rates has been reported. Fluo- 1,3 tion (CISH) (both measuring gene amplification). rescence in situ hybridization (FISH) is the universally accepted gold standard for confirming IHC 2+ cases and ambiguous results but is IHC assessment of HER2 neu status is practical, inex- costly and requires specialized equipment and technical expertise. pensive, familiar, and easily automated and is therefore the Chromogenic in situ hybridization (CISH) amalgamates the practical most commonly applied method used in http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

HER2 Positivity in Breast Carcinoma: A Comparison of Chromogenic In Situ Hybridization With Fluorescence In Situ Hybridization in Tissue Microarrays, With Targeted Evaluation of Intratumoral Heterogeneity by In Situ Hybridization

Loading next page...
 
/lp/wolters-kluwer-health/her2-positivity-in-breast-carcinoma-colon-a-comparison-of-chromogenic-nk7YfhO0tA

References (28)

Copyright
Copyright © 2005 by Lippincott Williams & Wilkins
ISSN
1541-2016
DOI
10.1097/01.pai.0000132189.01233.6d
Publisher site
See Article on Publisher Site

Abstract

TECHNICAL HER2 Positivity in Breast Carcinoma: A Comparison of Chromogenic In Situ Hybridization With Fluorescence In Situ Hybridization in Tissue Microarrays, With Targeted Evaluation of Intratumoral Heterogeneity by In Situ Hybridization Pequita Loring, BSc, Robert Cummins, BSc, Anthony O’Grady, MSc, and Elaine W. Kay, FRCPath a target-specific therapy that acts by inhibiting tyrosine kinase Abstract: An accurate and reproducible assay method for determin- 1,2 activity. Currently practiced laboratory methods for HER2 ing HER2 status is crucial, as a positive HER2 gene status is an eli- assessment include immunohistochemical (IHC) methods gibility requirement for Herceptin™ therapy. Although immunohis- (measuring increased protein expression) and fluorescence in tochemical (IHC) assessment is both practical and inexpensive, a Situ hybridization (FISH) and chromogenic in situ hybridiza- worrying trend of high false-positive rates has been reported. Fluo- 1,3 tion (CISH) (both measuring gene amplification). rescence in situ hybridization (FISH) is the universally accepted gold standard for confirming IHC 2+ cases and ambiguous results but is IHC assessment of HER2 neu status is practical, inex- costly and requires specialized equipment and technical expertise. pensive, familiar, and easily automated and is therefore the Chromogenic in situ hybridization (CISH) amalgamates the practical most commonly applied method used in

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: Jun 1, 2005

There are no references for this article.